It would add risks without addressing the true barriers — although note that the current system works pretty well.
“Let’s put a price tag on marrow donations,” by Michael Rush (Aug. 16), suggests that paying people to donate marrow for transplantation would improve the process.
We appreciate Mr. Rush’s decision to join the registry and his willingness to offer his marrow to save another individual. But, while well-intended, his proposal is based on a misunderstanding of the safety mechanisms underlying the donation of human organs and tissues. It would likely threaten the well-being of both patients and donors.
To be clear, volunteer altruistic donors never have to pay for donating or incur out-of-pocket costs. All aspects of marrow donation are covered, including medical expenses and travel, as well as things like meals, child care, pet sitting, hotel, Internet and more. Lost wages, which Rush specifically requested, are also provided when time away from work is not covered by an employer.
Outright monetary compensation of donors, however, could harm patients and donors. Substantial evidence shows that people who seek compensation for sharing their organs or cells are more likely to withhold pertinent medical information — information that could endanger not only the patient’s life, but also the donor’s. Paying donors might induce some to withhold information about their own health, which might make the currently very safe process of being a donor a bit riskier.
Donor honesty throughout the registration process is critical, because some potentially transmissible diseases such as mad cow disease or very early HIV infection do not show up on physical exams or by blood tests. Financial compensation for donation might alter how potential donors answer questions posed to identify activities or behaviors with the potential to expose recipients to such hazards. And unlike plasma, marrow and peripheral blood stem cells used for transplantation cannot be treated or sterilized once collected to protect against communicable diseases that a donor may not disclose.
Proponents of compensation argue that exposing patients to diseases like HIV and mad cow is a risk worth taking. We disagree. Any preventable risk to patient and donor safety is not worth taking, particularly when the current system is working.
Today, the majority of patients are able to find a matched donor on the national registry — a finding confirmed in a study published in the New England Journal of Medicine just last month. The study showed that a patient’s likelihood of having a suitably matched, available donor on the registry ranges from 66 percent to 97 percent, depending on the patient’s genetic makeup and ethnic background. Additionally, patients’ access to donated umbilical cord blood — which doesn’t need to match as closely as marrow — is improving these numbers even more.
Paying donors in the United States would actually decrease patients’ access to donors, because we would no longer conform to international standards under which such payment is prohibited. Nearly half of all transplants facilitated today involve an international patient or donor. Our partners in 41 countries are vital to maintaining patients’ access to donors across the world.
Rather than compensating individual donors, that money could actually save more lives by helping to cover the costs to add people to the national registry; funding critical research to improve transplant outcomes, and providing much-needed financial assistance to patients and caregivers.
Furthermore, other efforts to improve patients’ access to care — like broadening health insurance coverage for donor searching and transplantation and encouraging early referral to transplant — can measurably help more patients get the treatment they need.
The lack of insurance is still an obstacle that stands between some patients and the transplants they need. Most transplant centers do not accept patients who lack insurance or the ability to pay for the procedure. Costs to pay donors could add another financial barrier — keeping more patients from getting lifesaving care.
Patients without suitable health insurance also may not receive adequate treatment for their disease and may not be referred early enough to successfully receive a transplant. Research clearly shows that patients transplanted earlier in their disease have better outcomes. But too many patients — especially minorities — are referred too late.
On close examination, Rush’s proposal raises safety, moral and ethical concerns while not addressing the real barriers preventing patients from receiving the transplants they need.
We hope that Rush chooses to move forward and become a marrow donor, as many others have done and continue to do in return for the honor of saving another’s life.
Dr. Daniel Weisdorf, director of Adult Blood and Marrow Transplant at the University of Minnesota, is a past president of the American Society of Blood and Marrow Transplantation. Dr. Sergio Giralt, director of Blood and Marrow Transplant Service at Memorial Sloan Kettering Cancer Center, is the society’s president.
The Opinion section is produced by the Editorial Department to foster discussion about key issues. The Editorial Board represents the institutional voice of the Star Tribune and operates independently of the newsroom.